Recombinant Human PILR-beta Fc Chimera Avi-tag Protein, CF

When Recombinant Human CL-P1/COLEC12 (2690-CL) is immobilized at 2 μg/mL, 100 μg/mL, Biotinylated Recombinant Human PILR‑ beta Fc Chimera Avi-tag (Catalog # AVI9828) binds with an ED50 of 0.600-6.00 μg/mL.

2 μg/lane of Recombinant Human PILR-beta Fc Chimera Avi-tag Protein (Catalog # AVI9828) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-68 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human PILR-beta Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CL-P1/COLEC12 (Catalog # 2690-CL) is immobilized at 2 μg/mL, 100 μg/mL, Biotinylated Recombinant Human PILR‑ beta Fc Chimera Avi-tag binds with an ED₅₀ of 0.600-6.00 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human PILR-beta protein
  

  Human PILR- beta (Gln20-Ala189) Accession # Q9UKJ0.1	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: Q9UKJ0.1
• N-terminal Sequence: Gln20, as confirmed by mass spectrometry.
• Structure / Form: Biotinylated via Avi-tag.
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 48 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-68 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PILR-beta Fc Chimera Avi-tag Protein, CF

• activating receptor PILRbeta
• Activating receptor PILR-beta
• Cell surface receptor FDFACT
• cell surface receptor FDFACT1
• cell surface receptor FDFACT2
• FDFACT
• FDFACT1
• FDFACT2
• paired immunoglobin-like receptor beta
• paired immunoglobin-like type 2 receptor beta
• paired immunoglobulin-like receptor beta
• paired immunoglobulin-like type 2 receptor beta
• PILRB
• PILRbeta
• PILR-beta

Background

Paired immunoglobulin-like type 2 receptor beta (PILR-beta ) is a type I transmembrane (TM) glycoprotein that belongs to the Ig superfamily (1). PILR-beta is the activating counterpart to the inhibitory immunoreceptor PILR-alpha , forming a set of paired immune regulatory receptors responsible for regulating inflammatory responses (1). Mature human PILR-beta contains a V-type Ig-like extracellular domain (ECD) with a siglec-like fold, a single transmembrane domain, and a truncated cytoplasmic tail (2, 3). The transmembrane domain of PILR-beta contains a positively charged residue which interacts with immunoreceptor tyrosine-based activation (ITAM)-bearing adaptor molecules (2). The ECD of mature human PILR-beta shares 40% aa sequence identity with the ECD of mouse PILR-beta . PILR-beta is expressed on myeloid cells, such as natural killer, macrophage, and dendritic cells, as well as resident cells of the central nervous system, such as microglial cells (2,4). It is a binding partner for DAP12 and CD99, and has been shown to play an important role in innate immunity and inflammation (4-6). The PILR-alpha / beta pair have also been shown to regulate cell signaling via association with SHP-1 (7). Experiments studying the effects of S. aureus and T. gondii infections in mice have shown that up-regulation of PILR-beta led to significantly lower survival rates while knock-down of PILR-beta or activation of PILR-alpha resulted in significantly less inflammation and increased pathogen clearance (4,5). Our Avi-tag Biotinylated PILR-beta features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Wilson, M.D. et al. (2006) Physiol. Genomics 27:201.
2. Shiratori, I. et al. (2004) J. Exp. Med. 199:525.
3. Lu, Q. et al. (2014) PNAS 111:8221.
4. Tato, C.M. et al. (2012) PLoS One 7:e31690.
5. Banerjee, A. et al. (2010) Infect. Immun. 78:1353.
6. Tabata, S. et al. (2008) J. Biol. Chem. 283:8893.
7. Mousseau, D.D. et al. (2000) J. Biol. Chem. 275:4467

Bioinformatics

• Uniprot:
  • Q9UKJ0.1()